Literature DB >> 15489287

Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.

Charles Keller1, Benjamin R Arenkiel, Cheryl M Coffin, Nabeel El-Bardeesy, Ronald A DePinho, Mario R Capecchi.   

Abstract

Alveolar rhabdomyosarcoma is an aggressive childhood muscle cancer for which outcomes are poor when the disease is advanced. Although well-developed mouse models exist for embryonal and pleomorphic rhabdomyosarcomas, neither a spontaneous nor a transgenic mouse model of alveolar rhabdomyosarcoma has yet been reported. We report the first mouse model of alveolar rhabdomyosarcoma using a conditional Pax3:Fkhr knock-in allele whose activation in late embryogenesis and postnatally is targeted to terminally differentiating Myf6-expressing skeletal muscle. In these mice, alveolar rhabdomyosarcomas occur but at low frequency, and Fkhr haploinsufficiency does not appear to accelerate tumorigenesis. However, Pax3:Fkhr homozygosity with accompanying Ink4a/ARF or Trp53 pathway disruption, by means of conditional Trp53 or Ink4a/ARF loss of function, substantially increases the frequencies of tumor formation. These results of successful tumor generation postnatally from a target pool of differentiating myofibers are in sharp contrast to the birth defects and lack of tumors for mice with prenatal and postnatal satellite cell triggering of Pax3:Fkhr. Furthermore, these murine alveolar rhabdomyosarcomas have an immunohistochemical profile similar to human alveolar rhabdomyosarcoma, suggesting that this conditional mouse model will be relevant to study of the disease and will be useful for preclinical therapeutic testing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15489287      PMCID: PMC525542          DOI: 10.1101/gad.1244004

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  54 in total

1.  Activating mutations for the met tyrosine kinase receptor in human cancer.

Authors:  M Jeffers; L Schmidt; N Nakaigawa; C P Webb; G Weirich; T Kishida; B Zbar; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development.

Authors:  P N Tonin; H Scrable; H Shimada; W K Cavenee
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

3.  Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin.

Authors:  Charles Keller; Mark S Hansen; Cheryl M Coffin; Mario R Capecchi
Journal:  Genes Dev       Date:  2004-11-01       Impact factor: 11.361

4.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

5.  Multiple roles of Hoxa11 and Hoxd11 in the formation of the mammalian forelimb zeugopod.

Authors:  Anne M Boulet; Mario R Capecchi
Journal:  Development       Date:  2003-12-10       Impact factor: 6.868

6.  Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification.

Authors:  Taisuke Hosaka; William H Biggs; David Tieu; Antonia D Boyer; Nissi M Varki; Webster K Cavenee; Karen C Arden
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

7.  Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.

Authors:  Yukiko Takahashi; Yoshinao Oda; Ken-Ichi Kawaguchi; Sadafumi Tamiya; Hidetaka Yamamoto; Sachiyo Suita; Masazumi Tsuneyoshi
Journal:  Mod Pathol       Date:  2004-06       Impact factor: 7.842

8.  Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene.

Authors:  Alexander Fleischmann; Wolfram Jochum; Robert Eferl; James Witowsky; Erwin F Wagner
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

9.  Expression of CD44 by rhabdomyosarcoma: a new prognostic marker?

Authors:  G Humphrey; D L Hazel; K MacLennan; I Lewis
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

10.  The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo.

Authors:  Frédéric Relaix; Mariarosa Polimeni; Didier Rocancourt; Carola Ponzetto; Beat W Schäfer; Margaret Buckingham
Journal:  Genes Dev       Date:  2003-12-01       Impact factor: 11.361

View more
  142 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 2.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

3.  AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell.

Authors:  Mathivanan Jothi; Kochi Nishijo; Charles Keller; Asoke K Mal
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

4.  Zebrafish models of rhabdomyosarcoma.

Authors:  Eleanor Y Chen; David M Langenau
Journal:  Methods Cell Biol       Date:  2011       Impact factor: 1.441

Review 5.  New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.

Authors:  Göran Stenman; Mattias K Andersson; Ywonne Andrén
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

6.  Hedgehog/Patched-associated rhabdomyosarcoma formation from delta1-expressing mesodermal cells.

Authors:  F Nitzki; N Cuvelier; J Dräger; A Schneider; T Braun; H Hahn
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

7.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Authors:  Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan
Journal:  Cancer Discov       Date:  2014-01-23       Impact factor: 39.397

Review 8.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

9.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 10.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.